Good evening,

I would be interested to know which shares you can recommend from medium-sized companies with a medium investment horizon (approx. 1 year)!

Constructive discussions are also welcome werden☮️.

I'll throw something straight into the round:

$EUZ (+4,22%) stable with healthy growth (I've already posted this today🤫)

Hi, my name is Max, I'm 18 years old and I'm interested in social media and the stock market.

That's exactly why I'd like to document my financial career on Getquin from now on and talk about it with you. As you can probably tell from the name, my goal is to retire at the age of 50. I would like to make this possible through my share portfolio. Thanks to an inheritance, I had the opportunity to skip the hard road to the first €100,000. However, as I was only 15 years old at the time I found out about the inheritance, I had a lot to learn first. Now I'm 18 years old and already know a bit more. Over time, the stock market has become my hobby and hardly a day goes by when I don't spend time with it.

How it all began

As already mentioned, my interest in the stock market was triggered by the inheritance I received in 2019. Since the deceased relative also had a great interest in the stock market and had invested very successfully for many years, my father thought it would certainly be in his interest if I invested the money too. Fortunately, my father is also very experienced in the stock market, so he was able to explain a lot to me. So it wasn't long before I bought my first ETF with him. This was classically the $IWDA (+0,64%) . I also bought a fund for the Asian region $JQ8Y72 . At the time, this was a recommendation from a friend's bank. However, I sold this fund at some point with a loss of around 25%. That wasn't the best start, of course, but it did teach me how to deal with losses. In those early days, I learned a lot about the stock market from YouTube, but also from other platforms such as Der Aktionär and Finanzen100.

The first individual shares were added in 2023. That was back then $GOOGL (-1,98%) and $DHL (-0,46%) . This was followed by other tech giants such as $AMZN (+0,25%) , $MSFT (+1,32%) and $AAPL (+0,28%) . I now have 17 different individual stocks. Looking at my portfolio, most of them will probably be familiar to you, but there are also some smaller stocks like $EUZ (+4,22%) , $NHH (+0%) and $LNN (-0,7%) I bought because I find them exciting for the future.

Past and future

Fortunately, my portfolio has performed really well in recent years, in my opinion. This year, too, I am going into the new year with around 20%. Tech stocks in particular have performed strongly and generated decent returns. As I am very optimistic about the tech giants for the next few years, I will continue to hold them in my ETFs despite the doubling. As things stand today, however, I have 2 positions that I would like to change. $DHL (-0,46%) will probably be the first stock to leave my portfolio. Personally, I just don't have the feeling that the company is developing as strongly as many of my other shares. Of course the DHL share is great as a dividend stock, but I want to focus on growth first. That's exactly why I'm going to $GGRP (-0,39%) reallocation. The current replacement is the $FUSD (+0,31%) . I like the quality focus behind these ETFs, but I don't need GGRP's shifted focus on dividend stocks, as I don't really care about dividends at the moment.

In September 2025, I will start my apprenticeship as a bank clerk. From then on, I plan to finally set up my first savings plan. As I'll still be living at home at this point, it should be easy to save a high proportion of my trainee salary. But I'm also making sure that it's not too high - after all, I don't want my quality of life to suffer because of my savings.

Building up additional income

I have been very interested in social media since 2020. When I was 14 years old, I started an Instagram page and reached over 25,000 subscribers within 1-2 years. During this time, I was doing really well financially and I experienced some really great things. For example, I raffled off 120 liters of beer to my community with a brewery. But I'll write a post about that in my subscriber feed soon. After all, the whole thing doesn't really have anything to do with the stock market, which is why I don't want to burden the homepage with it. However, if any of you are still interested, feel free to follow me and read the story soon.

There I will also explain again why I can no longer use the site.

I'm currently trying my hand at YouTube. I'm using artificial intelligence to create videos in the hotel niche. The results are surprisingly good. More on that soon ;)

I'm also currently trying to build up my reach on Instagram. I recently opened an account on Instagram, which should address the same topics as this Getquin account. If you are interested, you are of course welcome to drop by. I'll try to add the link to the account here:

Generation Aktienrente 📈| Vermögensaufbau mit 18 (@aktienrente.mit.50) • Instagram-Fotos und -Videos

With the help of these projects, I hope to be able to build up a more or less passive income in the future, which I can then put directly into my share portfolio. However, to be honest, I also enjoy them as they are, which is why an additional income is not absolutely necessary.

Nevertheless, I will upload regular updates to my feed, which will document my current projects and their developments in detail.

End

This brings us to the end of my first article. I hope I have been able to arouse the interest of at least a few of you and would of course be delighted to receive feedback and suggestions for improving my portfolio and my plans.

I wish you all a happy new year!

Analyst updates, 28.11.

⬆️⬆️⬆️

- HAUCK AUFHÄUSER IB raises the price target for ECKERT & ZIEGLER from EUR 55 to EUR 56.50. Buy. $EUZ (+4,22%)

- EXANE BNP raises the target price for FREENET from EUR 30 to EUR 34. Outperform. $FNTN (-0,06%)

- HAUCK AUFHÄUSER IB raises the price target for NORTHERN DATA from EUR 45 to EUR 52. Buy. $NB2 (+2,95%)

- WARBURG RESEARCH raises the price target for PATRIZIA from EUR 9.80 to EUR 9.90. Buy. $PAT (+2,53%)

- DEUTSCHE BANK RESEARCH raises the price target for EASYJET from GBP 6.70 to GBP 7.15. Buy. $EZJ (-2,25%)

- EXANE BNP upgrades TRATON to Outperform. Target price EUR 35. $8TRA (+0,68%)

- JPMORGAN raises the price target for CTS EVENTIM from EUR 101 to EUR 104. Overweight. $EVD (+2,58%)

⬇️⬇️⬇️

- BRYAN GARNIER lowers the price target for LVMH from EUR 800 to EUR 770. Buy. $MC (+0,33%)

- KEPLER CHEUVREUX lowers the price target for PORSCHE SE from EUR 48 to EUR 47. Buy. $PAH3 (+1,4%)

- DEUTSCHE BANK RESEARCH lowers the price target for SYMRISE from EUR 130 to EUR 125. Buy. $SY1 (-0,1%)

- WARBURG RESEARCH lowers the price target for ABO ENERGY from EUR 114 to EUR 110. Buy. $AB9 (-0,24%)

- EXANE BNP lowers the target price for 1&1 from EUR 15 to EUR 12. Neutral. $1U1 (+0,83%)

- EXANE BNP lowers the price target for UNITED INTERNET from EUR 20 to EUR 17. Neutral. $UTDI (+2,18%)

- STIFEL downgrades COMPUGROUP from Buy to Hold and lowers target price from EUR 64 to EUR 18. $COP (+0,54%)

- BARCLAYS lowers the price target for SCHOTT PHARMA from EUR 33 to EUR 27. Equal-Weight. $1SXP (+1,48%)

- UBS lowers the price target for VESTAS from DKK 245 to DKK 175. Buy. $VWS (+0,6%)

Analyst updates, 25.11.

⬆️⬆️⬆️

- MORGAN STANLEY upgrades ROBINHOOD to Overweight. Target price USD 55. $HOOD (+1,7%)

- BARCLAYS raises the price target for DEUTSCHE TELEKOM from EUR 37 to EUR 39.50. Overweight. $DTE (-2,85%)

- BERENBERG raises the target price for SIEMENS ENERGY from EUR 35 to EUR 70. Buy. $ENR (+2,01%)

- UBS raises the target price for RHEINMETALL from EUR 570 to EUR 630. Neutral. $RHM (+0,16%)

- BARCLAYS raises the price target for 1&1 from EUR 17 to EUR 20. Equal-Weight. $1U1 (+0,83%)

- DEUTSCHE BANK RESEARCH upgrades VESTAS from Hold to Buy. $VWS (+0,6%)

- DEUTSCHE BANK RESEARCH raises the price target for VONOVIA from EUR 33 to EUR 38. Buy. $VNA (+0,1%)

- DEUTSCHE BANK RESEARCH raises the price target for TAG IMMOBILIEN from EUR 16 to EUR 18. Buy. $TEG (+0%)

- DEUTSCHE BANK RESEARCH upgrades AROUNDTOWN from Sell to Hold. Target price EUR 2.80. $AT1 (+0,64%)

- DEUTSCHE BANK RESEARCH raises the price target for LEG IMMOBILIEN from EUR 90 to EUR 105. Buy. $LEG (+0,64%)

- DEUTSCHE BANK RESEARCH upgrades DEUTSCHE WOHNEN from Hold to Buy and raises target price from EUR 19 to EUR 28. $DWNI (+0,44%)

- STIFEL raises the price target for NOVARTIS from CHF 106 to CHF 109. Hold. $NUVN

- DEUTSCHE BANK RESEARCH upgrades JD SPORTS FASHION from Sell to Hold. $JD. (-0,54%)

- DEUTSCHE BANK RESEARCH raises the price target for ALSTOM from EUR 22 to EUR 25. Buy. $ALO (+1,49%)

- MORGAN STANLEY raises the price target for DEUTSCHE BÖRSE from EUR 213 to EUR 232. Equal-Weight. $DB1 (+0,76%)

- KEPLER CHEUVREUX raises the target price for ECKERT & ZIEGLER from 57.30 EUR to 60.30 EUR. Buy. $EUZ (+4,22%)

- BARCLAYS raises the target price for UNITED INTERNET from EUR 23 to EUR 26. Equal-Weight. $UTDI (+2,18%)

- JEFFERIES raises the price target for HEIDELBERG MATERIALS from 142.10 EUR to 145.50 EUR. Buy. $HEI (+3,61%)

⬇️⬇️⬇️

- DEUTSCHE BANK RESEARCH lowers the price target for KION from EUR 55 to EUR 50. Buy. $KGX (+5,51%)

- DEUTSCHE BANK RESEARCH lowers the price target for CTS EVENTIM from EUR 114 to EUR 106. Buy. $EVD (+2,58%)

- GOLDMAN downgrades ORSTED from Buy to Neutral and lowers target price from DKK 520 to DKK 445. $ORSTED (-2,04%)

- DEUTSCHE BANK RESEARCH lowers the price target for H&M from SEK 200 to SEK 190. Buy. $HM B (-1%)

- MORGAN STANLEY lowers the price target for MERCK KGAA from EUR 200 to EUR 190. Overweight. $MRK (+3,78%)

- BARCLAYS lowers the target price for THYSSENKRUPP from EUR 4.40 to EUR 4. Underweight. $TKA (+2,28%)

- MORGAN STANLEY downgrades ING to Equal-Weight. Target price EUR 17.50. $ING (-3,15%)

- JPMORGAN lowers target price for RWE from EUR 48 to EUR 47.50. Overweight. $RWE (+0,06%)

Eckert Ziegler Q3 2024 $EUZ (+4,22%)

Financial performance:

• Sales growth: Sales increased by 17% to € 215.5 million (previous year: € 183.9 million), indicating strong demand, particularly in the medical sector.
• Net income: Net income increased by 15% to 23.4 million euros, reflecting a positive earnings trend.
• EBIT: EBIT before special effects increased by 9.0 million euros to 46.7 million euros, indicating improved operating efficiency.

Balance sheet overview:

• Total assets: Increase to 481 million euros (previous year: 439 million euros), indicating growth and increased investments.
• Equity: Increase of 26.2 million euros to 250.3 million euros.
• Liabilities: Loan liabilities fell by 4.8 million euros to 21.5 million euros, reducing the debt burden.

Details of the profit and loss account:

• Gross profit: Increased to 106.9 million euros (previous year: 89.8 million euros), due to margin improvements and sales growth.
• Cost of sales: Slight increase to 19.8 million euros (previous year: 18.8 million euros).
• General and administrative expenses: Increased to 33.4 million euros (previous year: 28.9 million euros), possibly due to investments in the corporate structure.

Cash flow overview:

• Operating cash flow: Significant increase to 45.1 million euros (previous year: 17.5 million euros), indicating strong cash management.
• Investing activities: Cash outflow reduced to 1.4 million euros (previous year: 19.8 million euros), indicating a more cautious investment policy.
• Financing activities: Outflow of 15.9 million euros, possibly for debt repayment or dividends.

Key figures and profitability metrics:

• Equity ratio: 52%, showing a solid capital base.
• Earnings per share (EPS): Increased to 1.12 euros (previous year: 0.98 euros), adding value for shareholders.

Segment information:

• Medical segment: External sales increased by 26% to 104.5 million euros, driven by demand in the pharmaceutical radioisotope segment.
• Isotope Products segment: Sales increased by 10 % to 111.0 million euros, indicating stable growth in this segment.

Competitive position: The company demonstrates a strong market position in the medical segment, particularly in the area of radioisotopes for pharmaceutical applications, which represents a significant growth area.

Forecasts and management commentary: The management plans to use excess liquidity to finance new projects in the medical segment, which will enable further growth in a segment with high potential.

Risks and opportunities:

• Currency effects: Positive impact on the Group result by 0.4 million euros.
• Discontinued operations: Losses from wound-up business increased from 3.1 million euros to 5.9 million euros, which could have a negative impact on profitability.

Summary of results:

Positive aspects:

• Sales growth: Solid growth of 17%.
• Increased profitability: Net profit increase of 15% and increase in operational efficiency.
• Strong segment growth: The medical segment recorded a 26% increase in sales.
• Improved operating cash flow: Strong cash generation for future investments.
• Stronger equity and reduced debt: Increased financial stability.

Negative aspects:

• Losses from discontinued operations: Increased loss from discontinued operations negatively impacts earnings.
• Higher administrative costs: Possible reduction in efficiency due to increased general costs.
• Slight increase in selling costs: Could put slight pressure on margins.
• Cash outflow from financing activities: Potentially a constraint on investment flexibility.
• Write-downs and depreciation in the "Other" segment: Burden on profitability.

And already my first article 🥳

Today Eckert & Ziegler published $EUZ (+4,22%) published its results for the first nine months of 2024 and reports continued growth. Sales increased by 17% to € 215.5 million compared to the previous year. EBIT (earnings before interest and taxes) from continuing operations increased by 24% to € 46.7 million. Net profit rose by 15% to 23.4 million euros or 1.12 euros per share. The main driver continued to be the pharmaceutical radioisotope business, supplemented by growth in other product groups.

Sales in the Medical Devices segment rose by 26% to 104.5 million euros. The Isotope Products segment achieved an increase of 10% to 111 million euros. The forecast for the year as a whole has been confirmed: The Management Board continues to expect annual sales of around 265 million euros and EBIT of 55 million euros.

In my opinion, this is a solid result with decent sales growth, which illustrates the strength of the company.

More details are available on the company website: Eckert & Ziegler Pressemitteilung .

The news is based on what I personally consider to be reputable sources. However, I do not guarantee their accuracy.

Analyst updates, 05.11.

⬆️⬆️⬆️

- ODDO BHF raises the price target for BIONTECH from USD 110 to USD 130. Outperform. $BNTX (-14,01%)

- BARCLAYS raises the price target for AIRBUS from EUR 161 to EUR 165. Overweight. $AIR (+2,53%)

- CITIGROUP raises the price target for SCOUT24 from EUR 91 to EUR 94.50. Buy. $G24 (+0,1%)

- WARBURG RESEARCH raises the price target for REDCARE PHARMACY from EUR 174 to EUR 176. Buy. $RDC (-0,7%)

- DEUTSCHE BANK RESEARCH raises the price target for RYANAIR from EUR 17 to EUR 17.50. Hold. $RYA (-1,03%)

- BERNSTEIN rates EBAY from Market-Perform to Outperform. Target price USD 70. $EBAY (+0,76%)

- ODDO BHF raises the price target for SALZGITTER from EUR 14 to EUR 15.50. Underperform. $SZG (-0,59%)

- BARCLAYS raises the target price for COMMERZBANK from EUR 16 to EUR 17. Equal-Weight. $CBK (-2,13%)

- BARCLAYS raises the target price for MTU from EUR 295 to EUR 340. Equal-Weight. $MTX (+5,29%)

- MORGAN STANLEY rates LUFTHANSA to Equal-Weight. Target price EUR 7. $LHA (+1,45%)

- BERENBERG raises the price target for DEUTSCHE KONSUM REIT from EUR 3.50 to EUR 5. Hold.

⬇️⬇️⬇️

- GOLDMAN lowers the price target for MERCEDES-BENZ from EUR 65 to EUR 63. Buy. $MBG (+1,59%)

- UBS lowers target price for 1&1 from EUR 21.60 to EUR 21. Buy.

- WARBURG RESEARCH lowers the price target for GFT TECHNOLOGIES from EUR 40 to EUR 37.50. Buy. $GFT (+0,22%)

- HAUCK AUFHÄUSER IB lowers the price target for ECKERT & ZIEGLER from EUR 63.50 to EUR 55. Buy. $EUZ (+4,22%)

- BARCLAYS lowers the price target for BNP PARIBAS from EUR 90 to EUR 85. Overweight. $BNP (+0,71%)

- BERENBERG downgrades SCHNEIDER ELECTRIC from Buy to Hold and lowers price target from EUR 261 to EUR 255. $SU (+2,74%)

- BERENBERG lowers the price target for BEFESA from EUR 41 to EUR 31. Buy. $BFSA (+1,96%)

Hey, why does $EUZ (+4,22%) part of information technology? It's actually pharma, isn't it? @Kundenservice

$PTP (-0,08%) Pentixapharm,

What exactly is the company that was spun off from Eckert and Ziegler? $EUZ (+4,22%) was spun off?

Andreas Eckert - founder of Eckert on this:

4 active ingredients including 2 in phase III and 2 in I/IIa

Target 2027 to bring both phase III diagnostics to market with EUR 55m expenditure.

However, further financing measures are required here.

20.8 million shares + 3.9 million in free float.

Other competitors in the market are

Telix Pharma and $TLX (+0,88%)

Lantheus Holding $LNTH (+0,24%)

Is the spin-off implemented automatically or do I have to book the new securities myself? $EUZ (+4,22%)